Haemostatix's topical haemostat, PeproStat, is based on coupling  multiple fibrinogen-binding peptides to a soluble carrier, thus forming a highly active fibrinogen-binding site (Figure A). When sprayed onto blood, the product polymerises fibrinogen to form a fibrin-like clot, without the need for thrombin. It can also be added to purified fibrinogen to form an exogenous clot or ‘seal’ over a wound. This new mode of action, based on peptide:protein recognition, is significantly faster than the enzymic action of thrombin, resulting in improved control of bleeding (Figure B). The new haemostat is also simple to manufacture with a highly competitive cost of goods. Two formulations are currently under development:  PeproStat S – this product consists of the polymerising agent alone (i.e. it acts on fibrinogen at the wound site), and will compete with thrombins. PeproStat G – this product consists of the polymerising agent plus added fibrinogen, and will compete with fibrin sealants. Trials in surgical models (Figure B) have demonstrated superior haemostatic effect.